Natriuretic peptides - New diagnostic markers in heart disease;Natriuretische peptide - Neue diagnostische marker bei herzerkrankungen

Herz

Volumn 29, Issue 6, 2004, Pages 609-617

  Angermann, Christiane E ^a   Ertl, Georg ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Diagnostic marker; Dyspnea; Heart failure; Natriuretic petides; Prognosis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; DIURETIC AGENT; N TERMINAL ATRIAL NATRIURETIC FACTOR PRECURSOR; N TERMINAL BRAIN NATRIURETIC PEPTIDE PRECURSOR; NATRIURETIC FACTOR; PROTEIN PRECURSOR; SPIRONOLACTONE; UNCLASSIFIED DRUG;

AGE; ALGORITHM; BRAIN NATRIURETIC PEPTIDE BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC MARKER; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DRUG EFFECT; DRUG MONITORING; DYSPNEA; ECHOCARDIOGRAPHY; FUNCTIONAL ASSESSMENT; GENDER; GERMANY; HEART ATRIUM; HEART DISEASE; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE OVERLOAD; HEART LEFT VENTRICLE VOLUME; HEART MUSCLE CELL; HEART SYSTOLIC FUNCTION; HEART VENTRICLE; HEART VENTRICLE COMPLIANCE; HEREDITY; HOSPITALIZATION; HUMAN; MORTALITY; NEW YORK HEART ASSOCIATION CLASSIFICATION; PATIENT SELECTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; PROTEIN SYNTHESIS; RELIABILITY; REVIEW; SYSTOLE;

EID: 5444252928     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-004-2619-8     Document Type: Review

References (47)

1. Benedict CR, Francis GS, Shelton B, et al. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. Am J Cardiol 1995;75:1151-7.
2. Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392-7.
3. Bibbins-Domingo K, Ansari M, Schiller NB, et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul Study. Circulation 2003;108:2987-92.
4. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000;2:198-2O5.
5. Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
6. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53.
7. Crazier IG, Nicholls MG, Ikram H, et al. Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition. Clin Exp Pharmacol Physiol 1989;16:417-24.
8. Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
9. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
10. Fujimura M, Yasumura Y, Ishida Y, et al. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail 2000;6:3-10.
11. Gottlieb SS, Kukin ML, Ahern A, et al. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9.
12. Hall C, Rouleau JL, Moye L, et al. N-terminal proatrial natriuretic factor. An independent predictor of long-term prognosis after myocardial infarction. Circulation 1994;89:1934-42.
13. Hartmann F, Packer M, Coats AJ, et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP Substudy. Eur J Heart Fail 2004;6:343-50.
14. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart and Lung Transplantation; endorsed by the Heart Failure Society of America. Circulation 2001;04:2996-3007.
15. Inoue S, Murakami Y, Sano K, et al. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000;6:92-6.
16. Logeart D, Thabut G, Jourdain P, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635-41.
17. Luchner A, Hengstenberg C, Lowel H, et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 2002;39:99-104.
18. Luchner A, Holmer S, Schunkert H, et al. Bedeutung der Herzinsuffizienzmarker BNP und NT-proBNP für die Klinik. Dtsch Ärztebl 2003;100:A3314-21.
19. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
20. Maeda K, Tsutamoto T, Wada A, et al. High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1587-93.
21. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
22. Maisel AS, McCord J, Nowak RM, et al. Bedside B-type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol 2003;41:2010-7.
23. Maisel AS, McCullough PA. Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. Rev Cardiovasc Med 2003;4:Suppl 4:S3-12.
24. Marie PY, Merles PM, Hassan-Sebbag N, et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Coll Cardiol 2004;43:353-9.
25. McDonagh TA, Holmer S, Raymond I, et al. NT-proBNP and the diagnosis of heart failures pooled analysis of three European epidemiological studies. Eur J Heart Fail 2004;6:269-73.
26. Mehra MR, Uber PA, Park MH, et al. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590-5.
27. Morita E, Yasue H, Yoshimura M, et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993;88:82-91.
28. Mueller C, Scholar A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
29. Nielsen OW, McDonagh TA, Robb SD, et al. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003;41:113-20.
30. Omland T, Bonarjee W, Lie RT, et al. Neurohumoral measurements as indicators of long-term prognosis after acute myocardial infarction. Am J Cardiol 1995;76:230-5.
31. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
32. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002;40:976-82.
33. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004;109:176-81.
34. Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 2002;4:11-22.
35. Richards AM, Doughty R, Nicholls MG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001;37:1781-7.
36. Rousseau MF, Gurne O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002;40:1596-601.
37. Ruskoaho H. Cardiac hormones as diagnostic tools in heart failure. Endocr Rev 2003;24:341-56.
38. Sanderson JE, Chan WW, Hung YT, et al. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failures double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 1995;174:502-7.
39. Sodian R, Loebe M, Schmitt C, et al. Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems. J Am Coll Cardiol 2001;38:1942-9.
40. Sumida H, Yasue H, Yoshimura M, et al. Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 1995;25:1105-10.
41. Tang WH, Girod JP, Lee MJ, et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003;108:2964-6.
42. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
43. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997;96:509-16.
44. Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 2003;108:13-6.
45. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655-63.
46. Wright SP, Doughty RN, Pearl A, et al. Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 2003;42:1793-800.
47. Yamaguchi H, Yoshida J, Yamamoto K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol 2004;43:55-60.